8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatocellular carcinoma annually affects over 700,000 people worldwide and trends indicate increasing prevalence. Patients ineligible for surgery undergo loco-regional treatments such as transarterial chemoembolization (TACE) to selectively target tumoral blood supply. Using a microcatheter, chemotherapeutics are infused followed by an embolic agent, or the drug is encapsulated by the embolic moiety; simultaneously inducing stasis while delivering localized chemotherapy. Presently, several products are used, but no universally accepted system is promoted because very disparate limitations exist. The goal of this investigation was to design and develop in situ gelling recombinant silk-elastinlike protein polymers (SELPs) for TACE. Two SELP compositions, SELP-47K and SELP-815K, with varying lengths of silk and elastin blocks, were investigated to formulate a new embolic that was injectable through commercially available microcatheters. The goal was to develop a composition providing maximal permeation of tumor vasculature while exhibiting effective embolic activity. The SELPs evaluated remain soluble until reaching 37 °C, when irreversible transition ensues forming a solid hydrogel network. SELP-815K formulated at 12% w/w with shear processing demonstrated acceptable rheological properties and clear embolic capability under flow conditions in vitro. A rabbit model showed feasibility of embolization in vivo allowing selective occlusion of lobar hepatic arterial branches.

          Related collections

          Author and article information

          Journal
          Biomaterials
          Biomaterials
          Elsevier BV
          1878-5905
          0142-9612
          Jul 2015
          : 57
          Affiliations
          [1 ] Department of Bioengineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
          [2 ] Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA.
          [3 ] Department of Bioengineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA.
          [4 ] Veterans Affairs Hospital, Salt Lake City, UT 84108, USA.
          [5 ] Associated Regional and University Pathologists, Salt Lake City, UT 84107, USA.
          [6 ] Department of Bioengineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: hamid.ghandehari@pharm.utah.edu.
          [7 ] Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
          Article
          S0142-9612(15)00362-2 NIHMS684806
          10.1016/j.biomaterials.2015.04.015
          4429515
          25916502
          e96e0d39-0a3c-4e09-a501-a1fcc599a4a0
          History

          Embolization,Hepatocellular carcinoma,Recombinant polymers,TACE

          Comments

          Comment on this article